The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - MedImmune; Novartis
Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck; Novartis; Pfizer
Research Funding - Pfizer (Inst)
 
Stephen L. Chan
No Relationships to Disclose
 
Andrew X. Zhu
Consulting or Advisory Role - Merck
 
Jennifer J. Knox
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Merck
Research Funding - AstraZeneca
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Merck Serono; Novartis; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Astex Pharmaceuticals; Bayer/Onyx; Exelixis; Genentech/Roche
Travel, Accommodations, Expenses - Merck
 
Oliver Bautista
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Masatoshi Kudo
Honoraria - Ajinomoto; Bayer; Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Chugai Pharma; Kowa; Merck Sharp & Dohme; Taiho Pharmaceutical
Research Funding - Abbvie; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Merck Sharp & Dohme; Otsuka; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda